Challenge
The OncoNet Rhein-Main network strives to offer cancer patients access to novel therapies via ongoing clinical studies. Matching patients and studies is challenging due to the increasing complexity and continually evolving landscape of molecular data in oncology.

Solution
As a regionally networked partner of the Rhein-Main area, Molecular Health supports therapy decisions by clinicians and pathologists with the structured processing and interpretation of next-generations sequencing (NGS) tumor profiles. Partners of OncoNet Rhein- Main receive onsite training to incorporate MH Guide into their translation of molecular data into practicable treatment decisions.

Patient benefit
The coverage in MH Guide of latest research findings, treatment recommendations, and ongoing clinical trials offer healthcare providers of the OncoNet Rhein-Main a rapid and accurate overview of approved and investigational therapy options. With detailed information about detected variants, all stakeholders can engage in multidisciplinary discussions to identify the best path for a patient based on a shared understanding of NGS data and, thus, offer patients individualized care.

Challenge
To meet the rising demand in molecular analyses of a wide range of tumor types, the Institute of Pathology at the Charité Berlin looked to implement an effective and comprehensive solution for results interpretation of next-generation sequencing (NGS) data.

Solution
Molecular Health supports clinical routines in the Charité Institute of Pathology with the evaluation of NGS data from molecular analy- ses of various cancer types. The MH Guide software enables the rapid and transparent interpretation of molecular analyses, delivering patient-specific results in customized reports. MH Guide is used especially in the evaluation of large gene panels to perform the paral- lel analysis of multiple disease-relevant genes and the automated identification of diagnostic mutations.

Patient benefit
The long-standing collaboration between the Institute of Pathology at the Charité Berlin and Molecular Health grants patients access to personalized cancer treatment and to relevant clinical trials based on individual molecular tumor profiles. The partnership fosters the rapid, evidence-based interpretation of molecular diagnostic outcomes for all cancer types and thus, promotes effective discussions among the interdisciplinary members of the molecular tumor board.

Challenge
The rising demand for personalized treatment of cancer has forced oncologists and pathologists to grapple with a flood of data from genomic testing and a continually changing landscape of recommendations for therapies. Isolated interpretation of results from molecular tumor profiling can lead to unwanted disparities in patient care.

Solution
MH Guide supports the interpretation of cancer gene variants based on up-to-date clinical research and internationally recognized recommendations and guidelines. With a wide distribution to 20 laboratories, Gen Era facilitates the harmonized translation of genomic data into actionable treatment decisions.

Patient benefit
The collaboration between Molecular Health and Gen Era Diagnostics is a true example of how a game-changing product combined with the market reach of a visionary enabler can accelerate much needed improvements in cancer care. The use of MH Guide across multiple laboratories not only standardizes genomic data interpretation, but also streamlines the evaluation of individual cases by oncologists and molecular tumor boards. Both aspects make the promise of precision medicine a reality for more patients.